Bi Nan
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC (NCT06998719) | Bi Nan | 2025-07-01 |
Track Bi Nan automatically
Every clearance here is in the API, with alerts when new ones post.